These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10734027)

  • 1. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.
    Persico M; Persico E; Suozzo R; Conte S; De Seta M; Coppola L; Palmentieri B; Sasso FC; Torella R
    Gastroenterology; 2000 Apr; 118(4):760-4. PubMed ID: 10734027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels.
    Puoti C; Magrini A; Stati T; Rigato P; Montagnese F; Rossi P; Aldegheri L; Resta S
    Hepatology; 1997 Dec; 26(6):1393-8. PubMed ID: 9397976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.
    Martinot-Peignoux M; Boyer N; Cazals-Hatem D; Pham BN; Gervais A; Le Breton V; Levy S; Degott C; Valla DC; Marcellin P
    Hepatology; 2001 Nov; 34(5):1000-5. PubMed ID: 11679971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases.
    Montalto G; Zignego AL; Ruggeri MI; Giannini C; Soresi M; Monti M; Carroccio A; Careccia G; Di Martino D; Giannelli F
    Dig Dis Sci; 1997 Aug; 42(8):1703-7. PubMed ID: 9286237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).
    Puoti C; Castellacci R; Montagnese F; Zaltron S; Stornaiuolo G; Bergami N; Bellis L; Precone DF; Corvisieri P; Puoti M; Minola E; Gaeta GB
    J Hepatol; 2002 Jul; 37(1):117-23. PubMed ID: 12076870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years.
    Persico M; Perrotta S; Persico E; Terracciano L; Folgori A; Ruggeri L; Nicosia A; Vecchione R; Mura VL; Masarone M; Torella R
    J Viral Hepat; 2006 May; 13(5):290-6. PubMed ID: 16637858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study.
    Tsuji K; Yamasaki K; Yamanishi M; Kawakami M; Shirahama S
    J Gastroenterol Hepatol; 2001 May; 16(5):536-40. PubMed ID: 11350550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels.
    Itoh Y; Morita A; Nishioji K; Narumi S; Toyama T; Daimon Y; Nakamura H; Kirishima T; Okanoue T
    J Viral Hepat; 2001 Sep; 8(5):341-8. PubMed ID: 11555191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis.
    Bani-Sadr F; Barange K; Daoud F; Jacomet C; Bicart-See A; Rosenthal E; Cacoub P; Pol S; Perronne C; Carrat F;
    HIV Med; 2009 Aug; 10(7):417-21. PubMed ID: 19490173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects.
    Coltorti M; Romano M; Persico M; Morisco F; Tuccillo C; Caporaso N
    Infection; 1995; 23(1):33-6. PubMed ID: 7538100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase.
    Okanoue T; Makiyama A; Nakayama M; Sumida Y; Mitsuyoshi H; Nakajima T; Yasui K; Minami M; Itoh Y
    J Hepatol; 2005 Oct; 43(4):599-605. PubMed ID: 16024129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.
    Sangiovanni A; Morales R; Spinzi G; Rumi M; Casiraghi A; Ceriani R; Colombo E; Fossati M; Prada A; Tavani E; Minoli G
    Hepatology; 1998 Mar; 27(3):853-6. PubMed ID: 9500717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels.
    Carreño V; Pardo M; López-Alcorocho JM; Rodríguez-Iñigo E; Bartolomé J; Castillo I
    J Infect Dis; 2006 Jul; 194(1):53-60. PubMed ID: 16741882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological findings in asymptomatic hepatitis C virus carriers.
    Kodama T; Tamaki T; Katabami S; Katamuma A; Yamashita K; Azuma N; Kamijo K; Kinoshita H; Yachi A
    J Gastroenterol Hepatol; 1993; 8(5):403-5. PubMed ID: 7693008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
    Sánchez-Conde M; Berenguer J; Miralles P; Alvarez F; Carlos Lopez J; Cosin J; Pilar C; Ramirez M; Gutierrez I; Alvarez E
    Clin Infect Dis; 2006 Sep; 43(5):640-4. PubMed ID: 16886160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological assessment of hepatitis C virus infection in parenteral drug abusers.
    Papatheodoridis GV; Delladetsima J; Verghisi-Nikolakaki S; Malliori M; Krystallis A; Hatzakis A; Tassopoulos NC
    Am J Gastroenterol; 1995 Oct; 90(10):1843-6. PubMed ID: 7572906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features.
    Rostaing L; Izopet J; Cisterne JM; Arnaud C; Duffaut M; Rumeau JL; Puel J; Durand D
    Transplantation; 1998 Apr; 65(7):930-6. PubMed ID: 9565097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.